Finding the Best Value Investment in Healthcare (XLV, GILD)

Share it with your friends Like

Thanks! Share it with your friends!


Finding the Best Value Investment in Healthcare (XLV, GILD)
For our healthcare sector analysis, I gathered data from Thomson Reuters
and compiled the earnings and revenue estimates for 2017 and 2018, and calculated 2018 forward P/E ratio, EPS growth rate, PEG ratio, revenue growth, price-to-sales, and something I call the price-to-sales growth rate.
Celgene looks like it has a projected revenue growth rate
that would support the higher multiple, with revenue expected to grow by nearly 16% from 2017 to 2018.
Turning to expected revenue, most of these numbers seem reasonable, with a price-to-sales ratio in the three or four range.
With the P/E ratio column this ranking is inverted, because a high P/E is negative, so the best P/E stock got a one.
Meanwhile, revenue is expected to grow by 9%, and it trades at a reasonable price-to-sales ratio of 3.25.
In the table below, I imported my earnings and revenue data, sorted each column from highest to lowest,
and then assigned a value of 1 through 10, with one being the worst and ten being the best.


Write a comment